From Hive to Clinic: Evidence, Chemistry, Safety, and Clinical Translation of Bee-Derived Products in Human Health

Bee-derived substances are often grouped under broad labels such as bee products or apitherapy, but those labels conceal major differences in chemistry, route, dose, source material, clinical evidence, and risk. This review argues that honey, medical-grade honey, manuka-type honey, propolis, royal jelly, bee venom, venom immunotherapy, pollen, bee bread, beeswax derivatives, drone brood products, stingless bee honey, bee-associated microorganisms, toxic honey syndromes, and beehive-air practices should not be treated as one therapeutic category. The strongest human evidence in the field belongs to venom immunotherapy for patients with clinically relevant Hymenoptera venom allergy, not to general supplementation or folk bee-sting practices. Honey has narrower evidence in selected uses, including pediatric acute cough relief in children over one year of age and certain wound-care contexts, while medical-grade honey must be separated from food-grade honey because clinical dressings require controlled production, contaminant limits, and sterilization. Manuka-type honey has a distinctive chemical basis in methylglyoxal derived from dihydroxyacetone, but antibacterial grading does not by itself establish clinical efficacy for every promoted use. Propolis, royal jelly, beeswax alcohol fractions, pollen, bee bread, and stingless bee honey show varied chemical and biological activity, but human evidence remains limited, heterogeneous, or largely preclinical for many claims. The review maps bee-derived products by product identity, bee species, botanical source, chemistry, route, evidence level, clinical domain, safety risk, and research gap. It also treats infant botulism, anaphylaxis, contact dermatitis, venom reactions, mad honey poisoning, tutin contamination, pyrrolizidine alkaloids, pesticide residues, antibiotic residues, heavy metals, and adulteration as central translational concerns. The future of bee-product research depends on moving from broad apitherapy language to product-specific, evidence-graded, safety-aware clinical translation.